European Primary Care Cardiovascular Society

Substantial variation of time to benefit between cholesterol-lowering agents

Aug. 3, 2018 - Barter PJ, Waters DD. - J Clin Lipidol. 2018

An explorative study compared the timepoint at which outcome curves separate among 17 statin and 7 non-statin trials. Results suggest that futility should not be declared too early in trials.

Effects antihypertensive and lipid-lowering therapy on CV risk not influenced by lifestyle

Aug. 2, 2018 - Dagenais GR, et al. - J Am Heart Assoc. 2018

A post hoc analysis of a randomized trial showed reduced CVD risk after rosuvastatin therapy with and without candestartan/hydrochlorothiazide, regardless of the number of healthy lifestyle factors.

Lipids and food

July 11, 2018 - Prof. David Marais - Cape Town, South Africa
Prof. David Marais reviews the impact of various dietary lipids as they relate to the conventional lipoprotein profile in  persons who do not have significant metabolic defects, as well as the impact on persons with metabolic disease.

Prof. David Marais reviews the impact of various dietary lipids as they relate to the conventional lipoprotein profile in persons who do not have significant metabolic defects, as well as the impact on persons with metabolic disease.

The cardiovascular challenge for primary care in diabetes

July 10, 2018 - Prof. Richard Hobbs - Oxford, UK
Prof. Hobbs stresses  the importance of CVRM in primary care and how to manage this risk beyond glucose control.

Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.

PCSK9 inhibitor and statins highly effective in people with diabetes with ACS

June 25, 2018 - news

ADA 2018 Analysis of ODYSSEY OUTCOMES trial indicates people with diabetes and prior ACS benefit most from the combination of alirocumab and statins, compared to ACS survivors with prediabetes or with normal glucose levels

Lipid lowering: the evidence, the guidelines, the clinical reality

EPCCS CV Summit 2018

Mar. 16, 2018 - EPCCS 2018, Barcelona, Spain - Professor Frank Visseren, Utrecht, The Netherlands
A recording of the lecture by Prof. Visseren, on practical issues of managing elevated lipids and statins: why do many patients not take their medication, and how can we improve this?

EPCCS 2018 A recording of the lecture by Prof. Visseren, on practical issues of managing elevated lipids and statins: why do many patients not take their medication, and how can we improve this?

Google searches and statin-intolerance

May 16, 2018 - news

A Google-driven nocebo effect may underlie statin intolerance, as countries with many websites on statin side-effects showed a higher prevalence of statin intolerance.

CV benefit of long-term statin treatment far outweighs adverse effects, says EAS Consensus Panel

May 3, 2018 - Mach F et al., Eur Atheroscl Soc Consensus Panel - Eur Heart J, 2018

Based on objective and critical appraisal of the literature on potential adverse effects of statins, the EAS Consensus Panel concludes that statin treatment is remarkably safe.

Conventional lipid-lowering therapy does not get heFH patients to recommended LDL-c targets

May 1, 2018 - Hartgers ML et al., - J Clin Lipidol. 2018

A model assuming 100% adherence to maximal statin dose showed that only 10% of heFH patients with CHD would reach guideline-recommended LDL-c goal, and about half of those without CHD.

Variation in time to benefit among clinical trials of lipid-lowering therapies

Apr. 30, 2018 - Barter PJ, and Waters DD. - J Clin Lipidol 2018

Early benefit should not be expected with all lipid-lowering drugs, and the lack of outcome curve separation up to 30 months does not preclude eventual benefit.

Statins are underutilized in peripheral artery disease patients

Apr. 10, 2018 - Arya S et al. - Circulation. 2018

In a large community-based database, in patients with peripheral artery disease, statin therapy was associated with a significant reduction of amputations and mortality compared with no statin use.

Slides | Lipid-lowering: the evidence, the guidelines, the clinical reality

Mar. 15, 2018 - Barcelona, Spain - Prof. Frank Visseren - Utrecht, The Netherlands
**EPCCS 2018** Slides prepared and presented byProf. Frank Visseren (Utrecht, The Netherlands), here offered as an educational service.

EPCCS 2018 Slides prepared and presented byProf. Frank Visseren (Utrecht, The Netherlands), here offered as an educational service.